05
					Pharmaceutical preparations for the treatment of
 neuromuscular diseases and disorders, muscular dystrophies,
 central nervous system diseases and disorders, genetic
 diseases and disorders; pharmaceutical preparations based on
 morpholino oligomer technology platform for the treatment of
 neuromuscular diseases and disorders, muscular dystrophies,
 central nervous system diseases and disorders, genetic
 diseases and disorders, and for the regulation of protein
 production; pharmaceutical preparations that modulate rna
 expression for the treatment of neuromuscular diseases and
 disorders, muscular dystrophies, central nervous system
 diseases and disorders, genetic diseases and disorders, and
 for the regulation of protein production; gene therapy
 products, namely, gene delivery pharmaceuticals;
 pharmaceutical preparations for gene therapy, gene editing,
 and genome editing; gene therapy products in the nature of
 pharmaceuticals for the treatment of neuromuscular diseases
 and disorders, muscular dystrophies, central nervous system
 diseases and disorders, genetic diseases and disorders;
 biological preparations for the treatment of neuromuscular
 diseases and disorders, muscular dystrophies, central
 nervous system diseases and disorders, genetic diseases and
 disorders; viruses, viral vectors and viral constructs for
 the treatment of neuromuscular diseases and disorders,
 muscular dystrophies, central nervous system diseases and
 disorders, genetic diseases and disorders; pharmaceutical
 preparations, biological preparations and gene therapy
 products in the nature of pharmaceutical and biological
 preparations for the treatment of genetic disorders and
 diseases
				
				
			
			Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen